Trabectedin plus pegylated liposomal doxorubicin: the return of a treatment option for ovarian cancer

By Clare John  

Future Oncology, Vol. 9, Iss. 12, 2013-12 ,pp. : 1-1

Future Medicine

Access to resources Recommend Favorite

The Costs and Efficacy of Liposomal Doxorubicin in Platinum-Refractory Ovarian Cancer in Heavily Pretreated Patients

By Hensley M.L.   Hoppe B.   Leon L.   Sabbatini P.   Aghajanian C.   Chi D.   Spriggs D.R.  

Gynecologic Oncology, Vol. 82, Iss. 3, 2001-09 ,pp. : 464-469

Elsevier

Access to resources Recommend Favorite

Prospective assessment of quality of life in ovarian cancer patients receiving whole abdomen hyperthermia and liposomal doxorubicin

By Hahn C. A.   Jones E. L.   Blivin J. L.   Sanders L. L.   Yu D.   Dewhirst M. W.   Secord A. A.   Prosnitz L. R.  

International Journal of Hyperthermia, Vol. 21, Iss. 4, 2005-06 ,pp. : 349-357

Informa Healthcare

Access to resources Recommend Favorite

Phase II clinical trial with pegylated liposomal doxorubicin

By Poveda A.  

Sarcoma, Vol. 9, Iss. 3-4, 2005-09 ,pp. : 127-132

Informa Healthcare

Access to resources Recommend Favorite

Phase II study of liposomal doxorubicin and weekly paclitaxel for recurrent Mullerian tumors

By Campos S.M.   Matulonis U.A.   Penson R.T.   Lee H.   Berkowitz R.S.   Duska L.R.   Fuller A.F.   Wilson K.S.   Puchalski T.A.   Supko J.G.   Seiden M.V.  

Gynecologic Oncology, Vol. 90, Iss. 3, 2003-09 ,pp. : 610-618

Elsevier

Access to resources Recommend Favorite